









Markets
/
Stocks
/
nasdaq-hook
/

HOOKIPA Pharma Inc

HOOK

View Detailed Chart

0.885USD

-0.006-0.72%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

10.69MMarket Cap

LossP/E TTM



HOOKIPA Pharma Inc

0.885

-0.006-0.72%

Overview Company Financials

Financials

Intraday

30m

Today

-0.72%

5 Days

-3.77%

1 Month

-28.02%

6 Months

-53.65%

Year to Date

-55.96%

1 Year

-82.84%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts

HOLD

Current Rating

50.000

Target Price

3167.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

HOOKIPA Pharma Inc

HOOK

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(8)

Neutral(1)

Buy(0)

Indicators

Sell(2)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.020

Sell

RSI(14)

19.753

Oversold

STOCH(KDJ)(9,3,3)

9.714

Oversold

ATR(14)

0.059

Low Volatility

CCI(14)

-79.411

Neutral

Williams %R

92.895

Oversold

TRIX(12,20)

-1.459

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.898

Sell

MA10

0.930

Sell

MA20

1.056

Sell

MA50

1.281

Sell

MA100

1.193

Sell

MA200

1.813

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Ticker SymbolHOOK

CompanyHOOKIPA Pharma Inc

CEODr. Malte Peters, M.D.

Websitehttps://www.hookipapharma.com/